We are live on
!
Find out more
MS
Marshall & Sullivan Portfolio holdings
AUM
$216M
1-Year Est. Return
12.97%
This Fund
S&P 500
This Quarter
Est. Return
+1.59%
1 Year Est. Return
+12.97%
3 Year Est. Return
+82%
5 Year Est. Return
+98.09%
10 Year Est. Return
+292.06%
AUM
$77.6M
AUM Growth
-$1.01M
(-1.3%)
Cap. Flow
-$1.22M
Cap. Flow
% of AUM
-1.57%
Top 10 Holdings %
Top 10 Hldgs %
45.21%
Holding
65
New
1
Increased
2
Reduced
32
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPNC
Spectranetics Corp
SPNC
|
+$17.6K |
| 2 |
SRCL
Stericycle Inc
SRCL
|
+$8.24K |
| 3 |
Apple
AAPL
|
+$5.96K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$328K |
| 2 |
Starbucks
SBUX
|
+$114K |
| 3 |
Danaher
DHR
|
+$53.4K |
| 4 |
Stryker
SYK
|
+$49.2K |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$49K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.84% |
| 2 | Consumer Staples | 18.06% |
| 3 | Technology | 16.39% |
| 4 | Consumer Discretionary | 12.6% |
| 5 | Industrials | 8.67% |
Similar funds
DSN
ICM
FFAM
NWM
LA
APC
WTFG
SNWA
Marshall & Sullivan's Q2 2016 Portfolio in Review
As of Q2 2016, Marshall & Sullivan held 65 positions worth $77.6M, down 1.3% from $78.6M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Marshall & Sullivan's Q2 2016 filing shows 1 new, 2 increased, 32 reduced and 9 closed positions. Its largest new stake was Spectranetics Corp: 1,000 shares worth $18K. The largest sale was Alphabet (Google) Class C, an estimated $328K.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 31% a quarter earlier, followed by Consumer Staples and Technology.
- Marshall & Sullivan's largest Q2 2016 buy was Spectranetics Corp: 1,000 shares worth $18K.
- Marshall & Sullivan added most to Stericycle Inc in Q2 2016, an estimated $8.24K increase.
- Marshall & Sullivan's biggest Q2 2016 reduction was Alphabet (Google) Class C, cutting an estimated $328K.
- Marshall & Sullivan fully exited Regeneron Pharmaceuticals in Q2 2016, selling an estimated $49K.
- Marshall & Sullivan's ten largest holdings make up 45% of its $77.6M portfolio in Q2 2016.
- Marshall & Sullivan opened 1 new position and closed 9 in Q2 2016.
- Marshall & Sullivan's portfolio value fell 1.3% quarter-over-quarter to $77.6M.
Based on Marshall & Sullivan's 13F filing for Q2 2016, filed 12 Aug 2016.